Results 221 to 230 of about 2,138,197 (387)

Five Cases of Non-Hodgkin B-Cell Lymphoma of the Ovary [PDF]

open access: gold, 2014
Taylan Şenol   +6 more
openalex   +1 more source

A Modular DNAzyme for Precise Visualization and Intervention of Alternative Splicing Isoforms in Live Cells

open access: yesAdvanced Science, EarlyView.
A Stringent dUPlex‐activated Error Robust (SUPER) DNAzyme system enables real‐time imaging of alternative mRNA splicing (e.g., Bcl‐xL/Bcl‐xS) in living cells via target‐triggered split‐DNAzyme reassembly and dual‐color fluorescence. It also achieves mRNA‐selective knockdown through DNAzyme‐based gene regulation, serving as a versatile tool for splicing
Mengru Lin   +6 more
wiley   +1 more source

Dynamic Decoration of DNA Scaffolds for High‐Resolution Cancer Cell Subtyping

open access: yesAdvanced Science, EarlyView.
This study presents a dual‐mode imaging platform that utilizes self‐assembly and disassembly of DNA scaffolds for high‐resolution cancer cell detection. The structural rigidity of DNA scaffolds effectively prevents cellular internalization for over 300 min.
Xiaolin Hu   +15 more
wiley   +1 more source

The Role of microRNAs as Potential Biomarkers in Diffuse Large B-Cell Lymphoma. [PDF]

open access: yesNoncoding RNA
Panteli E   +7 more
europepmc   +1 more source

SIRT5–RAC2 Axis Drives Monocyte‐to‐Macrophage Differentiation to Promote Inflammatory Injury in Premature Ovarian Insufficiency

open access: yesAdvanced Science, EarlyView.
SIRT5 desuccinylates and stabilizes RAC2, activating CSF1R‐dependent signaling to drive monocyte differentiation into M0 macrophages and their polarization toward pro‐inflammatory M1 phenotypes in CTX‐induced premature ovarian insufficiency. Inhibiting the SIRT5‐RAC2 axis attenuates inflammation, reduces granulosa cell apoptosis, and preserves ...
Wenjing TanTai   +15 more
wiley   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

open access: yesAdvanced Science, EarlyView.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy